Established since 1951, Biose Industrie provides a full range of services as a CDMO for microbiome therapeutics (LPBs) and Next Generation Probiotics.

Biose Industrie is the world leading CDMO for microbiome therapeutics and Next Generation Probiotics. Our facilities comprise a center of excellence of 52 000m2 based in Aurillac, France and an applied tech transfer laboratory in Boston, USA.

Established since 1951, Biose Industrie provides a full range of services as a CDMO for microbiome therapeutics (LPBs) and Next Generation Probiotics.

Established since 1951, Biose Industrie provides a full range of services as a CDMO for microbiome therapeutics (LPBs) and Next Generation Probiotics.

Established since 1951, Biose Industrie provides a full range of services as a CDMO for microbiome therapeutics (LPBs) and Next Generation Probiotics.

2024年12月30日 · Biose’s year in review . Reflecting on 2024, I am incredibly proud of the achievements of our team at Biose Industrie: 600+ bacterial strains manufactured. 80+ drug substance batches and 25+ clinical drug product batches produced. 10 million finished products delivered globally.

2024年10月10日 · Microbiotica and Biose worked closely together, running 12 production runs over a 5-month period. The process required assessment of multiple variables including raw materials, culture conditions, anaerobic gas, and process parameters to get it right.

2020年10月16日 · Biose Industrie’s manufacturing practices (GMP) and facilities already pass muster with the European regulatory agencies, and the company is also making good progress toward its goal of becoming FDA approved.

Established since 1951, Biose Industrie provides a full range of services as a CDMO for microbiome therapeutics (LPBs) and Next Generation Probiotics.

2024年1月29日 · Established since 1951, Biose Industrie provides a full range of services as a CDMO for microbiome therapeutics (LPBs) and Next Generation Probiotics.